This clearance follows approval for the sale of Photofrin, a photodynamic therapy drug manufactured by Axcan Pharma that works in conjunction with Diomed's 630 nm laser and Optiguide fiber in the treatment of late-stage lung and esophageal cancers.
"Inmex has done an excellent job laying the ground work and preparing for the product launch over the last few months," said Peter Klein, Diomed CEO. "As in many other countries around the world, photodynamic drug therapy for the treatment of cancer has been received with significant acceptance and interest."